No Data
Sichuan Kelun Pharmaceutical's 2024 Profit Jumps 20%
Sichuan Kelun Pharmaceutical: Summary of the 2024 Annual Report
Sichuan Kelun Pharmaceutical: 2024 Annual Report
Express News | Sichuan Kelun Pharmaceutica Says 2024 Net Profit up 19.5% Y/Y
With EPS Growth And More, Sichuan Kelun Pharmaceutical (SZSE:002422) Makes An Interesting Case
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Why Investors Shouldn't Be Surprised By Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Low P/E
